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Summary
We investigated the molecular basis for osteolytic bone metastasis by selecting human breast cancer cell line subpopula-
tions with elevated metastatic activity and functionally validating genes that are overexpressed in these cells. These genes
act cooperatively to cause osteolytic metastasis, and most of them encode secreted and cell surface proteins. Two of
these genes, interleukin-11 and CTGF, encode osteolytic and angiogenic factors whose expression is further increased
by the prometastatic cytokine TGF. Overexpression of this bone metastasis gene set is superimposed on a poor-prognosis
gene expression signature already present in the parental breast cancer population, suggesting that metastasis requires
a set of functions beyond those underlying the emergence of the primary tumor.
Introduction a causal role in this process (Chambers et al., 2002; Woodhouse
et al., 1997). How different genes may cooperate to fulfill various
Metastasis, the spread and growth of tumor cells to distant requirements for the establishment of tissue-specific metasta-
organs, represents the most devastating attribute of cancer. A ses, and how the expression of metastasis-associated genes
notable feature of this process is the variation in metastatic relates to the events that gave rise to the original tumor, remain
tissue tropism displayed by different types of cancer (Chambers important open questions. Indeed, primary tumors may already
et al., 2002; Fidler, 2002). In the case of breast cancer, most contain a gene expression profile that is strongly predictive of
patients with advanced disease develop osteolytic bone metas- metastasis and poor survival, thus challenging the notion that
tases, which are a common cause of morbidity and sometimes metastatic ability is acquired late during tumor progression (Ra-
mortality (Boyce et al., 1999; Mundy, 2002). An incomplete un- maswamy et al., 2003; van ’t Veer et al., 2002).
derstanding of the molecular and cellular mechanisms underly- We investigated these questions using the MDA-MB-231
ing bone metastasis hinders the development of effective thera- human breast cancer cell line as a model system. These cells
pies that would eliminate or ameliorate this condition. form typical osteolytic bone metastases when inoculated into
The establishment and growth of metastases at distant sites the arterial circulation of mice. Their bone metastatic activity is
is thought to depend on interactions between tumor cells and enhanced by TGF (Yin et al., 1999), a ubiquitous cytokine that
the host environment. A classical view argues that during tumor inhibits growth of normal epithelia and early stage tumors but
progression, cancer cells acquire multiple alterations that render stimulates invasion and metastasis of aggressive tumors (De-
them increasingly competent to establish metastatic lesions in rynck et al., 2001; Massague´ et al., 2000). By in vivo selection
specific organs (Fidler and Kripke, 1977; Poste and Fidler, 1980). of MDA-MB-231 cells, we have isolated subpopulations with
Many genes have been identified whose increased expression enhanced metastatic abilities to either bone or the adrenal me-
dulla. By comparing the transcriptomic profile of these isolates,correlates with metastasis, and some have been shown to play
S I G N I F I C A N C E
Metastasis has long been thought to be the result of a small number of primary tumor cells acquiring certain genetic changes that
allow them to spread to and thrive in distant organs. This concept was recently challenged by the proposal that metastasis may be
directly driven by oncogenic mutations that exist in most cells of a primary tumor. Here we provide experimental evidence for the
concept that breast cancer metastasis to a specific tissue—bone—is mediated by a specific set of genes. A small percentage of
tumor cells in a human breast cancer cell line that possesses a recently described poor prognosis signature were able to metastasize
to bone by virtue of overexpressing these genes. Our findings provide a conceptual framework and an experimental system for the
identification of genes mediating metastasis to different organs.
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we identified a gene set whose expression pattern is associated cells (Figure 2B). Of note, the 1833 and 2287 populations are not
more aggressive than the parental population in the formation ofwith, and promotes the formation of, metastasis to bone but
not adrenal medulla. This gene expression profile is superim- subcutaneous tumors or proliferation in culture (data not
shown). This suggests that the increased bone metastatic activ-posed on a previously defined poor-prognosis gene expression
signature (van ’t Veer et al., 2002). Cells with the bone metastasis ity of these cells does not result from a faster growth rate, but
rather from the acquisition of specific metastasis-promotinggene profile are present in the parental population and become
selected in vivo as highly metastatic entities. Many genes in functions, including the ability to mobilize and recruit host osteo-
clasts.this group encode secretory or cell surface proteins implicated
in cell homing to bone, angiogenesis, invasion, and osteoclast Bone lesions generated by injection of 1833 were in turn
expanded in vitro in order to isolate second-cycle metastaticrecruitment, thus influencing the tumor microenvironment in
favor of metastasis. When overexpressed, these genes promote populations. These secondary isolates were then tested for met-
astatic activity in vivo (Figure 1B), which demonstrated that theosteolytic bone metastasis by acting cooperatively. Two of
these genes are further activated by TGF, suggesting a basis elevated bone metastatic activity of 1833 is a trait retained
during passage in vitro or in vivo. A similar conclusion could befor the prometastatic activity of this cytokine in bone. The results
point to key functions that must be acquired by poor-prognosis drawn for the 2287 cell population (data not shown). In compari-
son, second passage populations isolated from adrenal glandbreast cancer cells in order to manifest their bone metastasis
potential. metastases by 1834 remained poorly metastatic to bone (Figure
1B) and highly metastatic to the adrenal gland (data not shown).
Results
No enhanced expression of poor-prognosis gene
expression signature in metastatic cellsIn vivo selection of highly metastatic breast
cancer cells A 70-gene expression signature strongly predictive of metasta-
sis and poor survival was recently delineated by analysis ofCancer cell populations established from patients with ad-
vanced disease are thought to be heterogeneous, comprising tumors from breast cancer patients (van ’t Veer et al., 2002).
We investigated the possibility that the enhanced metastaticdifferent genomic characteristics and different abilities to metas-
tasize to distant secondary sites. In vivo selection may prove abilities of the in vivo selected population might correlate with
a gain in the expression of genes in this signature. Of 52 overex-effective in isolating highly metastatic subpopulations from the
original mixture (Clark et al., 2000; Fidler, 1973). Therefore, we pressed genes in the poor-prognosis signature (van ’t Veer et
al., 2002), 38 are present in the Affymetrix U133A GeneChip.used this approach for the identification of circulating breast
cancer cells with the ability to home and thrive at metastatic We compared the expression level of these genes in parental
MDA-MB-231 cells and several highly metastatic derivative pop-sites, especially bone (Figure 1A).
The breast cancer cell line MDA-MB-231 was isolated from ulations with the MCF10A, a cell line derived from normal human
mammary epithelium as a control (Soule et al., 1990). Fourteenthe pleural effusion of a patient with disseminated disease re-
lapsing several years after removal of the primary tumor (Cailleau of the 38 genes are overexpressed in parental MDA-MB-231
compared to MCF10A, two are underexpressed, and the restet al., 1974). These cells form bone metastases from the blood-
stream when inoculated into the left cardiac ventricle of immu- show little change (Figure 3A). This distribution is typical of
breast tumors with poor outcome (van ’t Veer et al., 2002). Ofnodeficient mice (Yin et al., 1999). Bone metastases become
detectable by X-ray imaging 10–12 weeks after inoculation of the 18 underexpressed genes in the poor-prognosis signature,
ten are present in the U133A GeneChip. Seven of these were105 parental MDA-MB-231 cells (obtained from the American
Type Culture Collection, ATCC), and appear in 30% of inocu- expressed at similar levels and three were overexpressed in
parental MDA-MB-231 compared to MCF10A (Figure 3A). Over-lated animals (Figure 1B). Human tumor cells were recovered
from such lesions, expanded in culture, and reinoculated into expression of these three particular genes has been observed
in several poor prognosis tumors (van ’t Veer et al., 2002). Over-mice. Subpopulations 1833 and 2287 obtained after one cycle
of in vivo selection generated large osteolytic bone lesions in all, then, the parental MDA-MB-231 population displays a pre-
viously defined poor-prognosis gene expression signatureonly 5–7 weeks in most of the inoculated animals (Figures 1B
and 1C; Table 1). Other populations obtained after one cycle (van ‘t Veer et al., 2002). This is in agreement with the poor
outcome of the particular case from which the MDA-MB-231of in vivo selection remained poorly metastatic to bone (Figures
1B and 1C), but some of them (e.g., 1834) exhibited high meta- cell line was derived (Cailleau et al., 1974).
The expression pattern of the breast cancer prognosis genesstatic activity toward the adrenal medulla (data not shown).
Bone lesions generated by the 1833 and 2287 populations in the highly metastatic subpopulations, however, showed little
are very osteolytic, invading the bone matrix along the entire rim difference with that in the parental MDA-MB-231 population
of the lesions they form (Figure 2A). These lesions incorporate (Figure 3A). Thus, the gain in bone metastatic activity by MDA-
numerous osteoclasts into the tumor mass and its periphery, MB-231 subpopulations does not involve an increased expres-
as determined by TRAP (tartrate-resistant acid phosphatase) sion of these poor-prognosis signature genes.
staining (Figure 2B). No TRAP-positive cells were observed in
association with 1833 and 2287 cells when grown as subcutane- Gene expression signature associated with osteolytic
bone metastatic abilityous tumors (data not shown). In contrast to the highly osteolytic
nature of the bone lesions formed by 1833 and 2287, those We compared the transcriptional profile of parental MDA-MB-
231 cells and twelve derivative subpopulations with differenteventually formed by 1834 and 1835, when allowed to grow to
a similar size, had a smooth periphery pressing the bone matrix metastatic potentials in order to identify genes that differ in their
expression between the weakly and the highly bone-metastaticwithout invading it (Figure 2A), and recruited few TRAP-positive
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Figure 1. In vivo selection of highly metastatic breast cancer cells
A: Schematic representation of the in vivo selection process. MDA-MB-231 cells were inoculated into the left cardiac ventricle of nude mice. Bone lesions
were detected by X-ray analysis 10–12 weeks after injection. Tumor cells were isolated from bone lesions and reinoculated after expansion in culture. Cells
isolated from the second round of metastases were expanded in culture and reinoculated to confirm their metastatic phenotype. RNA samples isolated
from these in vivo selected populations were subjected to gene expression profiling analysis to identify candidate metastasis-enhancing genes.
B: Kaplan-Meier curves showing the bone metastasis activity of the parental (ATCC) MDA-MB-231 cell population, various in vivo selected subpopulations,
and various populations derived from a second in vivo passage of the latter, as listed in Table 1. Metastasis was scored as the time to first appearance of
a visible bone lesion by X-ray imaging of the whole mouse. The percent of animals in each group that were free of detectable bone metastases is plotted.
** p  0.01, *** p  0.001 compared with the parental (ATCC). Data for second passage populations were pooled for the graphic representation; the
data corresponding to each individual population are shown in Table 1.
C: Top: Representative X-ray radiography of the hindlimbs of mice six weeks after inoculation with the parental MDA-MB-231 (ATCC) or the 1833 highly
metastatic population. Osteolytic lesions are indicated by arrows. Bottom: Representative H&E staining sections of the adrenal gland (arrows) from mice
12 weeks after inoculation of mice with parental MDA-MB-231 or the 1834 subpopulation. Large, bilateral adrenal metastases were evident in 1834 cell
line, but not the parental cell line.
groups (Figure 3B). One hundred and two genes represented expression signature present in the parental MDA-MB-231 cell
population.by 127 probe sets (Figure 3B) passed our filtering and statistical
comparison criteria (see Experimental Procedures). Forty-three Most of the genes in this group that are overexpressed by
more than 4-fold encode cell membrane or secretory productsgenes (52 probe sets) were selectively overexpressed in the
highly metastatic set, and 59 (75 probe sets) were underex- that may affect the host environment to favor metastasis (Figure
3C). They include the bone-homing chemokine receptor CXCR4pressed (Figure 3B). Thus, the populations that are highly meta-
static to bone have a distinct transcriptional signature not shared (Muller et al., 2001; Taichman et al., 2002); the angiogenesis
factors fibroblast growth factor-5 (Giordano et al., 1996) andby populations that are highly metastatic to the adrenal gland.
The identities of these genes are listed in the Supplemental Data connective tissue-derived growth factor (Moussad and Brig-
stock, 2000); the activator of osteoclast differentiation interleu-at http://www.cancercell.org/cgi/content/full/3/6/537/DC1. Inter-
estingly, none of the genes in the bone metastasis signature kin-11 (IL11, Manolagas, 1995); the matrix metalloproteinase/
collagenase MMP1, which promotes osteolysis by cleaving aidentified here are part of the previously defined poor-prognosis
breast cancer signature (van ’t Veer et al., 2002). Thus, the bone specific peptide bond in the collagen of bone matrix (Egeblad
and Werb, 2002; Holliday et al., 1997; Zhao et al., 1999); fol-metastasis gene-expression profile identified here is nonover-
lapping with, and superimposed on, a poor-prognosis gene listatin, which binds activin blocking its growth inhibitory effects
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metastatic to bone form a functionally heterogeneous groupTable 1. Incidence of bone metastasis generated by parental and various
including extracellular matrix components and receptors (lami-sublines of MDA-MB-231
nin 1, fibronectin, collagen type V, integrin 4), cytoskeletalMice with bone met (%)
MDA-MB-231 Derived Site of components (tubulin 1, keratin 7, periplakin), proteinases (ser-
subline from isolation 60 days 100 days pin A1, cathepsin B), class II major histocompatibility complex
components (HLA-DPA1, -DPB1, -DPB3), and putative tumorATCC 8/45 (18%) 14/45 (31%)
1833 ATCC Bone 22/25 (88%) 23/25 (92%) suppressors (N33, DLC1).
1834 ATCC Bone 1/15 (7%) 2/15 (13%)
2279 ATCC Bone 2/10 (20%) 5/10 (50%) A functionally diverse set of genes cooperatively2280 ATCC Bone 3/9 (33%) 5/9 (56%)
promote bone metastasis2287 ATCC Bone 9/10 (90%) 9/10 (90%)
2268 1833 Bone 5/5 (100%) 5/5 (100%) Four of the most highly overexpressed genes in bone metastatic
2269 1833 Bone 9/9 (100%) 9/9 (100%) populations, IL11, CTGF, CXCR4, and MMP-1, each represent-
2271 1833 Bone 5/9 (56%) 6/9 (67%) ing a distinct type of biological activity, were chosen to investi-
2274 1833 Bone 9/10 (90%) 9/10 (90%)
gate their ability to promote bone metastasis in vivo. Northern2293 1834 Adrenal 0/5 (0%) 1/5 (20%)
blot analysis of all four gene transcripts (Figure 3D) confirmed2295 1834 Adrenal 0/5 (0%) 2/5 (40%)
2297 1834 Adrenal 0/5 (0%) 0/5% (0%) the elevated expression of these genes in the populations highly
metastatic to bone.The ratio of mice displaying bone metastases to the total number of mice
is indicated for two time points, along with the percentage of mice bearing IL11 is a potent inducer of osteoclast formation from progen-
bone metastases (in parentheses). The origin of each cell population and itor cells in the bone marrow (Manolagas, 1995). Osteoclasts
the tissue from which it was isolated are also indicated. are direct mediators of bone resorption in osteolytic bone me-
tastases (Boyce et al., 1999; Mundy, 2002). We generated pools
of IL11-transfected parental MDA-MB-231 cells (Figure 4A) and
tested their metastatic activity in vivo. When overexpresed
(de Winter et al., 1996); the metalloproteinase-disintegrin family alone, IL11 did not significantly enhance bone metastasis forma-
member ADAMTS1 (Kuno et al., 1999); and proteoglycan-1 (Ti- tion by the parental population (Figure 4B). To search for genes
mar et al., 2002). that might collaborate with IL11 in bone metastasis, we scruti-
nized microarray data for candidates. Osteopontin (OPN) is con-The genes that are underexpressed in populations highly
Figure 2. Osteoclast recruitment by highly osteo-
lytic tumor cell populations
A: H&E staining of bone lesions generated by
various in vivo selected populations with different
metastatic potential to bone. In order to com-
pare lesions of similar size, the lesions produced
by the highly metastatic populations 6 weeks
after inoculation were compared with lesions
produced by the poorly metastatic populations
12 weeks after inoculation. The invasive nature
of the highly metastatic populations 1833 and
2287 was evident in the rugged interface be-
tween tumor mass and the bone matrix. In com-
parison, this feature is rarely seen in lesions gener-
ated by the 1834 and 2293 populations. Instead,
lesions generated by these two cell lines were
mostly smooth and pressing against the bone
matrix without invading it.
B: TRAP staining showing numerous osteoclasts
in the tumor mass and tumor/bone interface in
lesions generated by inoculation 2287 but not by
1834. Dotted line marks the bone matrix surface.
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Figure 3. A bone metastasis gene expression signature
A: Expression pattern of a previously identified poor-prognosis breast cancer genes (van ’t Veer et al., 2002) in the MCF-10A normal human mammary
epithelial cell line, parental MDA-MB-231 cells, and three MDA-MB-231 subpopulations of different metastatic potential. Data correspond to the 48 out of
the 70 poor-prognosis genes (van ’t Veer et al., 2002) that are represented in the U133A GeneChip. Each column represents one gene, and each row
one cell line. Genes that were expressed in higher or lower levels in poor prognosis tumors (van ’t Veer et al., 2002) are underlined by red or green bars,
respectively. Genes that were not expressed or expressed in very low level in all cell lines are shown in dark colors (low confidence).
B: Hierarchical cluster diagram of 127 filtered probe sets. Various in vivo selected cell lines were grouped according to their bone metastasis potential:
weak (green), mild (yellow), and strong (red). ATCC-1 and ATCC-2 are duplicated samples of the parental MDA-MB-231 population. Criteria used to filter
genes whose expression differs significantly between weak and strong metastatic groups are described in the Experimental Procedures. Each row represents
one gene, and each column one cell line. Varying levels of expression are represented on a scale from dark blue (lowest expression) to dark red (highest
expression).
C: Hierarchical cluster diagram of 11 genes (represented by 16 probe sets) among the 127 probe sets in B that differed by 4-fold in expression level
between weak and strong metastatic groups. The Affymetrix probe set number, fold difference, and identities of the genes are indicated. ADAMTS-1: A
disintegrin and metalloproteinase with thrombospondin motifs-1.
D: Confirmation of expression pattern of various metastasis-associated genes by Northern blot in the indicated cell populations.
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Figure 4. Cooperative metastatic activity of mul-
tiple bone metastasis genes
A: MDA-MB-231 cells were engineered to overex-
press IL11 or osteopontin (OPN) individually or
together. Cell culture supernatants from each
cell line were subjected to ELISA analysis for IL11
and OPN.
B, D, and E: Kaplan-Meier curves showing the
incidence of bone metastasis by parental MDA-
MB-231 cells (ATCC) and the indicated transfec-
tant derivatives. * p  0.05, ** p  0.01, and ***
p  0.001 compared with the parental (ATCC).
C: Total RNA of different pools of single or triple
transfectants used in D and E was harvested and
subjected to Northern blot analysis using the indi-
cated cDNA probes to confirm overexpression of
exogenous genes. Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was used as a control.
sistently overexpressed in highly metastatic cells (Figure 6A, nohistochemical analysis of the resulting lesions revealed the
presence of numerous TRAP-positive cells (data not shown).compare the first two lanes; and unpublished data), but was
When overexpressed alone in parental MDA-MB-231 cells,not present among the 102 filtered bone metastasis genes be-
CXCR4 caused a limited but significant increase in bone meta-cause it is also overexpressed in the cell populations that are
stasis formation, whereas CTGF did not (Figure 4D). However,highly metastatic to adrenal medulla (unpublished data). OPN
triple transfectants overexpressing IL11, OPN, and either CXCR4is a secretory protein with multiple functions, including the ability
or CTGF (Figure 4C) showed a dramatic increase both in theto stimulate osteoclast adhesion to bone matrix (Asou et al.,
rate and in the incidence of bone metastases (Figure 4E). The2001; Denhardt et al., 2001). OPN has been implicated in cancer
aggressiveness of these triple transfectants approached that of
metastasis to various organs (Furger et al., 2001; Hotte et al., the in vivo-selected highly metastatic populations. Preliminary
2002; Reinholz et al., 2002; Weber, 2001). As IL11 and OPN data suggest that overexpression of MMP1 alone or in combina-
play distinct roles in enhancing osteoclast function, we tested tion with IL11 and OPN also enhances bone metastasis. When
whether they could collaborate in promoting osteolytic bone grown as subcutaneous tumors or in culture, all these transfec-
metastasis. Indeed, the combined overexpression of IL11 and tants grew at the same rate as the parental cell population
OPN in parental MDA-MB-231 (Figure 4A) cells significantly (data not shown). Thus, the combined activities of these genes
specifically promote the growth of osteolytic bone metastases.augmented the incidence of bone metastasis (Figure 4B). Immu-
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TGF activates bone metastasis genes IL11 and CTGF MB-231 population. To this end, we isolated forty-six individual
In normal epithelia and low-grade tumors, TGF acts as a potent cells from the parental population by dilution cloning, and allowed
growth inhibitor by causing cell cycle arrest or apoptosis (Mas- them to multiply in culture. The resulting single-cell derived
sague´ et al., 2000; Roberts and Sporn, 1990). The TGF recep- progenies were analyzed for the expression of five metastasis
tors and their substrates and transcriptional mediators, the genes: IL11, MMP1, CTGF, CXCR4, and OPN. Several popula-
Smad proteins (Smad2 and Smad4), are tumor suppressors that tions were found to overexpress four or five of these genes
suffer inactivating mutations in cancer (Derynck et al., 2001; (Figure 6A). When these cells were inoculated into athymic mice,
Massague´ et al., 2000). In breast cancer, however, tumor cells they formed bone metastases more aggressively than the paren-
often show a selective loss of growth-inhibitory TGF response tal population (Figure 6B), at a rate that was comparable to that
without a concurrent loss of TGF receptor or Smad functions of the in vivo-selected 1833 and 2287 populations (refer to
(Chen et al., 2001; Derynck et al., 2001). In these cells, TGF Figure 1B). Populations overexpressing three of these genes
may instead stimulate tumor invasion and metastasis, turning (Figure 6A) had an intermediate metastatic activity (Figure 6B),
from a tumor suppressor into a tumor progression factor (De- and populations overexpressing just one were not more aggres-
rynck et al., 2001). In mouse model systems, administration of sive than the parental population (Figure 6B). Interestingly, pop-
TGF neutralizing agents decreases breast cancer metastasis ulations that do not express any of these metastasis-associated
(Muraoka et al., 2002; Yang et al., 2002). As TGF is abundantly genes failed to form detectable metastases for at least 8 months
stored in bone matrix (Mundy, 2002; Roberts and Sporn, 1990), after inoculation (Figure 6B, and data not shown).
it has been proposed that TGF released during osteolysis sup- The single-cell progenies could be segregated into two
ports a cycle of metastatic breast cancer stimulation (Mundy, groups, depending on the expression pattern of the 102 genes
2002). that constitute the in vivo-selected bone metastasis signature
MDA-MB-231 cells provide a good example of these alter- (Figure 6C). Remarkably, this gene expression pattern closely
ations, as they suffer a selective loss of TGF antiproliferative cosegregated with the metastatic activity of the single cell prog-
gene responses (Chen et al., 2001) and a gain of bone metastatic enies. Multidimensional scaling (MDS) analysis of the expression
TGF responsiveness in vivo (Yin et al., 1999). Metastasis forma- pattern of the 102 genes provided further evidence for the relat-
tion by MDA-MB-231 cells is partly dependent on the ability of edness of populations selected in vitro on the basis of express-
these cells to respond to TGF, as demonstrated by overexpres- ing the five metastasis genes and populations selected in vivo
sion of dominant-negative and constitutively activated TGF on the basis of their high metastatic activity (Figure 6D). In the
receptors in the cell line (Yin et al., 1999). An elevated secretion MDS analysis, these two sets of populations were clustered
of the osteolytic factor parathyroid-related protein (PTHrP) has together, well separated from the poorly metastatic populations.
been noted in TGF-stimulated MDA-MB-231 cells (Yin et al., To compare the composition of the parental and the in vivo-
1999). However, this effect occurs without an increase in PTHrP selected highly metastatic populations, we isolated single-cell
mRNA levels, and is not augmented in our highly metastatic progenies from 1833 and 2287 cell lines. We then analyzed the
cell populations (unpublished data). expression pattern of bone metastasis genes in these single-
Among the bone metastasis genes identified here, IL11 and cell progenies (Figure 6E). The proportion of cells expressing
CTGF have been previously reported to respond to TGF (Gro- each of the metastasis genes tested was dramatically increased
tendorst et al., 1996; Morinaga et al., 1997). We observed a in the 1833 and 2287 cell lines compared to the parental popula-
clear activation of these genes in the various cell populations tion (Figure 6F).
used in our study (Figures 5A and 5B). In populations highly We performed comparative genomic hybridization (CGH)
metastatic to bone, TGF further increased the already high analysis on the parental MDA-MB-231 population and its in
level of IL11 and CTGF expression (Figures 5A and 5B). The
vivo or in vitro selected derivatives with different metastatic
high basal expression of these genes in the highly metastatic
potentials. As expected, the chromosomal profile of these differ-
populations did not result from autocrine stimulation by TGF,
ent populations is highly aberrant compared to normal humanas determined by using TGF-neutralizing antibodies (data not
cells (see Supplemental Data at http://www.cancercell.org/cgi/shown).
content/full/3/6/537/DC1). However, the profile of the differentThe TGF signaling pathway involves Smad2 and Smad3
MDA-MB-231 subpopulations is very similar despite the markedas direct substrates of the TGF receptor and Smad4 as their
differences in metastasis gene patterns and metastatic activitiespartner in the formation of transcriptional complexes (Massague´,
of these subpopulations. Some differences are present between1998). To determine whether the Smad pathway participates in
the CGH profiles of the highly metastatic populations versusTGF-mediated induction of IL11 and CTGF in MDA-MB-231
the weakly metastatic ones, including loss of chromosomal re-cells, we mapped the TGF responsive regions in the corre-
gions in 2q and 7q and gain in 12q and 14q. However, thesesponding gene promoters (unpublished data) and used this in-
differences are highly consistent among cells selected in vivoformation to perform chromatin immunoprecipitation (ChIP)
by their metastatic abilities or in vitro by their metastasis geneassays (Figure 5C). TGF addition rapidly induced the binding
profile. Collectively, these results indicate that the bone meta-of Smad2/3 and Smad4 to the relevant regions of the IL11 and
stasis gene expression pattern of populations 1833 and 2287CTGF promoters. Therefore, IL11 and CTGF induction via the
is not a result ongoing chromosomal alteration during the selec-canonical TGF/Smad pathway in the metastatic cells may par-
tion of these cells in vivo or their passage in vitro. We concludeticipate in a bone metastasis cycle driven by paracrine TGF.
that that the tumor-derived MDA-MB-231 population contains
natural variants with a bone-metastasis gene signature and highEvidence for in vivo selection of preexisting
metastatic activity to bone; these variants become selected inmetastatic cells
vivo by virtue of their high propensity to form fast-growing boneWe wished to determine whether the highly metastatic cells
isolated through in vivo selection preexist in the parental MDA- metastases.
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Figure 5. IL11 and CTGF are transcriptional tar-
gets of TGF via the Smad pathway
A: Parental and derivative MDA-MB-231 popula-
tions were incubated in the presence () or ab-
sence () of 100 pM of TGF1 for 3 hr. Total RNA
was subjected to Northern blot analysis with the
indicated probes.
B: Cell cultures were washed and treated with
TGF or no additions for 24 hr. IL11 production in
the media was determined using an ELISA assay.
Data are the average of triplicate determin-
ations  S.D.
C: MDA-MB-231 cells were left untreated () or
treated () with TGF for 2 hr, and chromatin
immunoprecipitations were performed with the
indicated antibodies. PCR was performed with
primers specific for the IL11 and CTGF promoter
regions encompassing the TGF responsive ele-
ments. Primers specific for the -actin promoter
were used for the negative controls.
Discussion this gene expression signature, suggesting a basis for the tissue
specificity.
Only a fraction of the cells in the particular breast cancer popula- The most prominently overexpressed genes in this bone
tion studied here have the ability to form highly aggressive, metastasis signature encode mostly cell surface and secretory
osteolytic bone metastases. A different fraction in the same proteins, each of them with functions that may alter the host
tissue environment to foster formation of osteolytic bone lesionspopulation has the ability to form aggressive metastases in the
adrenal medulla. Thus, metastatic ability is not a uniform trait (Figure 7). These functions (and the genes encoding them) in-
clude bone marrow homing and extravasation (CXCR4) (Mullerin a breast cancer cell population.
The ability to form aggressive bone metastases is tightly et al., 2001), pericellular proteolysis and invasion (MMP1,
ADAMTS1) (Egeblad and Werb, 2002; Holliday et al., 1997; Kunoassociated with a distinctive expression profile of a defined set
of genes. Cell populations isolated in vivo for their propensity et al., 1999), angiogenesis (FGF5 and CTGF) (Giordano et al.,
1996; Moussad and Brigstock, 2000), osteoclastogenesis (IL11)to form bone metastases display this gene expression signature.
Concordantly, single cell progenies that show this signature (Manolagas, 1995), growth factor regulation (follistatin) (de Win-
ter et al., 1996), and extracellular matrix alteration (proteogly-manifest a high propensity to form bone metastases. This signa-
ture is retained through repeated passage of the metastatic cell can-1) (Timar et al., 2002).
Our functional assays provide evidence for a causal role ofpopulation in vitro and in vivo. Therefore, breast cancer cells
with a defined tissue-specific metastatic ability preexist in the IL11, CTGF, and CXCR4, along with OPN, in osteolytic metasta-
sis formation. High expression of CXCR4 (Geminder et al., 2001;parental tumor cell population and have a distinctive bone me-
tastasis gene expression signature. Formation of bone metasta- Muller et al., 2001; Taichman et al., 2002), IL11 (Sotiriou et al.,
2001), and osteopontin (Hotte et al., 2002; Reinholz et al., 2002)ses is the result of selection and enrichment of these preexisting
high expressers of the bone metastasis profile. Cell populations in human cancer has been clinically correlated with bone metas-
tasis. For these particular genes, our work provides an importantthat are highly metastatic to the adrenal medulla do not share
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Figure 6. Evidence of in vivo selection of preexisting, highly metastatic cells
A: Forty-six single cells were randomly picked from the parental MDA-MB-231 population, expanded in culture, and subjected to Northern blot analysis
using the six indicated probes. Cells tested in functional metastasis analysis are highlighted by colored boxes.
B: Kaplan-Meier curves showing the bone metastasis activity of the parental MDA-MB-231 population (ATCC) and the indicated single-cell derived
populations. * p  0.05 and *** p  0.001 compared with parental cells. Cell lines that do not express any of the 5 genes generated no bone metastasis
for up to 6 months after inoculation. Data for the High IL11 and High-4 groups were pooled.
C: Two-way hierarchical cluster diagram of the expression pattern of 127 filtered probe sets in 11 single-cell derived populations. In the dendrogram,
populations are segregated into two major clusters that coincide with highly metastatic (purple) and weakly metastatic (teal) phenotypes. Each row
represents one gene, and each column one cell line.
D: Multidimensional scaling plot illustrating the relationship among parental population, populations selected in vivo based on metastatic activity, and
single-cell derived populations identified in vitro based on the expression pattern of 5 bone metastasis genes. Red and purple dots represent samples from
the highly metastatic in vivo selected populations (Figure 3B) and single-cell derived populations, respectively. Green and teal dots represent samples
from weakly metastatic in vivo selected populations (Figure 3B) and single-cell derived populations, respectively.
E: Sixteen and ten single cell progenies (SCPs) were randomly generated from the 1833 and 2287 populations, respectively, and subjected to Northern
blot analysis using the indicated probes. Number of metastasis genes overexpressed in each SCP is indicated above each lane of samples.
The percentage of cells in parental, 1833, and 2287 populations overexpressing the indicated metastasis genes is summarized in F.
confirmation of their relevance to metastasis by showing func- affect metastatic activity when individually overexpressed in
poorly metastatic cells. However, the combined overexpressiontional evidence of their prometastatic effect in a mouse model.
At the same time, their identification as prometastatic genes in of as few as three of these genes—IL11 and OPN combined
with either CXCR4 or CTGF—endowed cells with a level ofour studies provides a validation of our approach as an unbiased
means of identifying genes of relevance to human cancer metas- metastatic activity close to that of the highly aggressive cell
populations endogenously expressing the entire bone metasta-tasis. Most genes in our set, however, have not been shown to
play a causal role in metastasis and could become potential sis gene set. Formation of aggressive bone lesions therefore
requires the cooperation of several genes that fulfill complemen-candidates for new diagnostic markers and therapeutic targets.
Most of the bone metastasis genes identified here did not tary functions.
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Figure 7. Bone-tropic metastasis is mediated by
distinct classes of metastasis genes
A schematic model depicting molecular mech-
anisms underlying breast cancer metastasis as
mediated by several of the genes in the present
bone metastasis gene set. Primary breast tumor
arises from normal mammary epithelium through
the accumulation of oncogenic mutations. A
small proportion of cancer cells in the primary
tumor population accumulate additional ge-
netic changes that mediate metastasis to the
bone. Elevated expression of functionally distinct
classes of metastasis-enhancing genes in these
tumor cells cooperatively enables their invasion,
colonization, and destruction of bone matrix. De-
struction of bone matrix releases stored growth
factors, including TGF, which causes a further
increase in the expression of the TGF-responsive
metastasis genes, CTGF and IL11, and establishes
a positive feedback metastasis cycle.
The bone-specific metastasis genes identified here may ad- ture may seem surprising. However, each of the genes that we
have identified is likely to be utilized by only a fraction of breastditionally cooperate with genes that are not exclusive to the
cancer tumors metastasizing to bone, and their overexpressionbone metastasis phenotype. Examples of the latter class include
may emerge late in the course of the disease. On both counts,PTHrP, which is expressed in parental MDA-MB-231 cells and
such genes would not score in studies seeking to identify badwhose proosteolytic activity contributes to bone metastasis (Yin
prognosis signatures shared by a large proportion of primaryet al., 1999), and OPN, a multifunctional adhesion factor whose
tumor samples. The observed incidence of CXCR4, IL11, andoverexpression is observed in many metastatic tumors (Furger
osteopontin overexpression in clinical samples of metastaticet al., 2001; Hotte et al., 2002; Reinholz et al., 2002; Weber,
tumors (Geminder et al., 2001; Hotte et al., 2002; Hynes, 1976;2001). We observe OPN overexpression both in populations
Muller et al., 2001; Sotiriou et al., 2001; Taichman et al., 2002)highly metastatic to bone and in those highly metastatic to
is consistent with these considerations.adrenal medulla. In our functional assays, OPN promoted bone
Tumor progression is considered the result of cumulativemetastasis when overexpressed in combination with IL11. As
oncogenic alterations. Once an original set of transformingan enhancer of osteoclast adhesion to bone matrix (Asou et al.,
events gives rise to a primary tumor, the tumor cells may accu-2001), OPN may leverage the osteoclast differentiation function
mulate further genetic and epigenetic alterations that dynami-of IL11 (Manolagas, 1995). Also relevant are the activities spe-
cally affect their transcriptional profile. For cancer cells to metas-cifically decreased in the bone-metastatic populations, in partic-
tasize to bone, certain complementary functions that may beular several extracellular matrix proteins and proteases whose
irrelevant to primary tumor formation need to be progressivelydownregulation is in line with the important role of extracellular
fulfilled. These functions include homing to the bone marrow,matrix alterations in invasion and metastasis (Cavallaro and
invasion, angiogenesis, or osteoclastogenesis. In the case ofChristofori, 2001; Hynes, 1976).
MDA-MB-231, these functions may be carried out by CXCR4,The long-standing hypothesis that metastatic cells are rare
CTGF, IL-11, and OPN, with contributions from other genesand arise late during tumor progression (Fidler and Kripke, 1977;
in our gene set yet to be functionally tested. The functionsPoste and Fidler, 1980) has been challenged by the finding that
contributed by CXCR4, CTGF, IL-11, or OPN could be fulfilledthe clinical outcome of breast cancer patients can be predicted
by different mediators in other tumors. The establishment ofby a poor-prognosis gene expression signature present in the
metastatic lesions may be driven by selection of a set of stochas-primary tumor (Bernards and Weinberg, 2002; Ramaswamy et
tically accumulated functions, rather than selection of a specifical., 2003; van ’t Veer et al., 2002). Our results may bridge the gap
set of overexpressed genes. Therefore, a reiteration of the pres-between these two views. In agreement with the latter hypothesis,
ent experiments with other breast cancer cell models shouldwe find that the parental MDA-MB-231 cell population possesses
provide a more complete view of alternative mediators of bonethe poor-prognosis gene expression signature. However, we
metastasis and a basis for the delineation of their incidence inalso find that additional functions, provided by a concrete set
the breast cancer patient population at large.of bone metastasis genes, must be expressed in order to
achieve an overt, tissue-specific metastasis phenotype. Thus, Experimental procedures
the bone metastasis gene expression signature identified here
is superimposed on a poor-prognosis gene expression signa- Intracardiac injections
Cell were harvested from subconfluent cell culture plates, washed with PBS,ture. We propose that the poor-prognosis gene expression sig-
and resuspended at 106/ml concentrated in PBS. 0.1 ml of the suspendednature enables the emergence of metastatic cells, whereas the
cells was injected into the left cardiac ventricle of 4-week-old, female BALB/bone metastasis gene expression signature identified here exe-
c-nu/nu nude mice (NCI) using 26G needles as previously described (Yin et
cutes the metastatic potential of such cells. al., 1999). Mice were anesthetized with ketamine (100 mg/kg body weight)
The absence of an overlap between the present set of bone and xylazine (10 mg/kg body weight) before injection. A successful injection
was characterized by the pumping of arterial blood into the syringe.metastasis genes and a poor-prognosis gene expression signa-
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Radiographic analysis of bone metastasis pass this restriction. Of the 102 genes, 43 are overexpressed and 59 are
underexpressed in the highly metastatic group. Detailed information aboutDevelopment of bone metastases was monitored by X-ray radiography.
Mice were anesthetized, arranged in prone position on single-wrapped films these 102 genes can be found in our Supplemental Data at http://www.
cancercell.org/cgi/content/full/3/6/537/DC1.(X-OMAT AR, Eastman Kodak, Rochester, NY), and exposed to an X-ray at
35 kV for 15 s using a Faxitron instrument (Model MX-20; Faxitron Corp., We carried out one- or two-way hierarchical clustering analysis using
the Genespring 5.0 software (Silicon Genetics). We used centroid linkageBuffalo, IL, USA). Films were developed using a Konica SRX-101A processor
and inspected for visible bone lesions. clustering with standard correlation as similarity metric. MDS was performed
to visualize the similarity of gene expression profile between any pair of
samples. Samples with similar gene expression profiles (shorter distances)Isolation of tumor cells from osteolytic bone lesions
were placed near each other in the three-dimensional MDS plot and sepa-To isolate tumor cells from the osteolytic lesions, mice with lesions detected
rated from other dissimilar groups (longer distance). MDS analysis was car-by radiography were sacrificed, and the affected forelimbs or hindlimbs were
ried out using an implementation in the R Statistical Software packageseparated from the body at the joints. Both ends of the long bone were cut
downloaded from www.r-project.org. Data matrix and analysis commandsopen after skin and muscle were removed using a scalpel. A 1 ml syringe
could also be found in the Supplemental Data.with a 26G needle was filled with PBS and inserted into one end of the
bone. Mouse bone marrow cells as well as tumor cells were forced out from
Single-cell derived populationsthe other end by applying pressure to the syringe. Cells were collected by
MDA-MB-231 cells were trypsinized, washed with PBS, and resuspendedcentrifuge and washed once with PBS before being cultured in 5 cm plates
at 10 cells/ml, 5 cells/ml, and 2.5 cells/ml concentrations. 100 l of eachusing regular MDA-MB-231 culture media. Mouse bone marrow cells did
suspension was added to each well of a 96-well plate. After two weeks, wellsnot attach to the plate and could be washed off with PBS after the tumor
harboring single colonies were identified by observation under microscope.cells became attached. After one to two weeks of culture, a pure population
Colonies were trypsinized from the well and expanded until reaching 80%of human cancer cells was obtained, as confirmed by FACS analysis using
confluency in a 10 cm tissue culture plate. Total RNA samples were harvesteda FITC-conjugated anti-human HLA-A, B, C antibody (32294x, Pharmingen).
from each clone and subjected to Northern blot analyses.
Histological analysis
ELISA analysisForelimb and hindlimb long bones of nude mice injected with cancer cells
The production and secretion of IL11 and OPN by parental MDA-MB-231were excised, fixed in 10% neutral-buffered formalin, decalcified, and then
cells and various subpopulations or stable transfectants were determinedembedded in paraffin and stained with hematoxylin and eosin (H&E). The
in 24 hr-conditioned media using commercially available IL11 (R&D Systems)kidneys and adrenal glands were removed from affected mice, fixed in
and OPN (Assay Designs, Inc.) ELISA kits according to the manufacturer’s10% neutral-buffered formalin overnight, and dehydrated through a graded
instructions.alcohol series and stored at 4 	C in 70% ethanol until processing. Following
complete alcohol dehydration, the tissues were embedded in paraffin and
Comparative genomic hybridization (CGH)H&E staining performed. Histological services were provided by Histoserv
CGH was performed using standard procedures (Kallioniemi et al., 1992).Inc. (Gaithersburg, MD).
Briefly, 1 g DNA was labeled by nick translation using FITC-dUTPFor TRAP-staining, monoclonal mouse anti-TRAcP antibody (clone ZY-
(NEN-DuPont) (cell line) or Texas Red-dUTP (NEN-DuPont) (normal female9C5; Zymed Laboratories, San Francisco, CA) was used at 1:50 final dilution.
control), purified through spin columns, coprecipitated with 25 g Cot-1Avidin-biotin immunoperoxidase method with antigen retrieval was applied.
DNA (Invitrogen), resuspended in hybridization buffer, and hybridized toBriefly, deparaffinized sections were treated with 1% H202 to block endoge-
normal metaphase spreads for 48–72 hr. After standard stringency washes,nous peroxidase, followed by boiling sections in citric acid (0.01 M, pH 6.0)
the slides were stained with DAPI and mounted in Vectasheild mountantin a microwave oven for 15 min to enhance antigen retrieval. Mouse Ig
(Vector Labs). Image analysis was performed using the Isis digital imagingblocking reagent (M.O.M Vector Laboratories, Inc, Burlingame, CA) and
system (Metasystems). Data for CGH analysis can be found in the Supple-10% normal horse serum were used to block nonspecific tissue reactivities.
mental Data.Primary antibody was applied for an overnight incubation at 4	C. Biotinylated
horse anti-mouse IgG (Vector Laboratories, Inc) was used at 1:500 dilution
Chromatin immunoprecipitation assayfor 30 min, followed by avidin-biotin complex (Vector Laboratories, Inc) at
ChIP assays were carried out as described (Takahashi et al., 2000) using1:25 dilution and 30 min incubation. Diaminobenzidine with 0.1% H202 was
MDA-MB-231 (ATCC) cells. Antibodies used were anti-Smad2/3 (Kretz-used as the final chromogen and hematoxylin as the nuclear counterstain.
schmar et al., 1999) and anti-Smad4 (Calonge and Massague´, 1999). PrimerGranular cytoplasmic staining was considered positive immunoreactivity.
sets 5
-CCAACTTTTCCTTCCGTGCCC-3
 and 5
-GCATGTGCCCTGAGCA
GCAGG-3
 were used to amplify a 200 bp region of the IL11 promoterMicroarray data analysis
containing the previously defined TGF responsive fragment. Primer setsAbsolute analysis of each chip was carried out using the Affymetrix Microar-
5
-CCTCTTCAGCTACCTACTTCC-3
 and 5
-GACATTCCTCGCATTCCTCray Suite 5.0 Software to generate raw expression data. Parental and several
CCCC-3
 were used to amplify a 300 bp region of the CTGF promoterin vivo selected sublines of MDA-MB-231 cell line were divided into two
harboring a previously identified TGF responsive region. The primer setgroups (weakly metastatic and highly metastatic, see Figure 2A) according
used to amplify the promoter region of -actin was as described (Takahashito their metastatic potential to bone. To find genes that associated with
et al., 2000).metastasis phenotype, we applied three different filtering and statistical
analysis constraints to the expression data to exclude those genes that did
Statistical analysisnot vary significantly between comparison groups, or that were not ex-
We created Kaplan-Meier survival curves using Stata 7.0 Software (Statapressed in a high enough level in either one of the two groups. First, statistical
Corporation, College Station, TX). Log-rank test were used to calculate thegroup comparison was carried out to find genes that show statistically
statistical significance (p value) of difference between metastasis curves.significant differences in mean expression levels between the two groups.
Log of ratio normalized expression data was analyzed with cross-gene error
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